MPLT

Peers: LBRX ACAD NMRA BMY ANRO NBIX CTNM AXSM ABBV PRTA

| Held by: IWM VXF VTI IWO VTWO SCHA FESM VHT IWC VTWG

Index	RUT
Market Cap	421.26M
Enterprise Value	118.52M
Income	-229.83M
Sales	0.00M
Book/sh	7.67
Cash/sh	5.48
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	133
IPO	Oct 27, 2025

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.99
P/C	1.38
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	16.52
Current Ratio	16.52
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-5.12
EPS next Y	-3.91
EPS next Q	-1.20
EPS this Y	73.35%
EPS next Y	21.01%
EPS next 5Y	40.14%
EPS past 3/5Y	-71.59% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-83.91%
Sales Q/Q	-
Earnings	Aug 13 AMC
EPS/Sales Surpr.	2.16% -

Insider Own	78.03%
Insider Trans	12.28%
Inst Own	26.88%
Inst Trans	-1.40%
ROA	-101.59%
ROE	-111.55%
ROIC	-65.84%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-8.70%
SMA50	-27.49%
SMA200	-63.05%
Trades

Shs Outstand	45.44M
Shs Float	12.21M
Short Float	27.21%
Short Ratio	6.40
Short Interest	3.32M
52W High	40.43 -81.25%
52W Low	7.44 1.88%
Volatility	7.31% 7.19%
ATR (14)	0.63
RSI (14)	31.48
Beta	3.01
Rel Volume	0.00
Avg Volume	518.84K
Volume	0

Perf Week	-4.89%
Perf Month	-21.29%
Perf Quarter	-39.60%
Perf Half Y	-75.31%
Perf YTD	-56.85%
Perf Year	-58.74%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.43
Target Price	25.75
Prev Close	7.58
Price	7.58
Change %	0.00%

Consensus

Strong Buy

Avg. Price Target

$25.75

Implied Upside

+239.7%

Analysts13incl. previous ratings

Rating Distribution10 Buy · 3 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 06, 2026	Initiated	GGuggenheim	Neutral
Aug 10, 2026	Downgrade	UUBS	Buy → Neutral	$13	+71.5%
Jul 28, 2026	Downgrade	MMorgan Stanley	Overweight → Equal-Weight	$21	+177.0%
Jul 21, 2026	Initiated	BBMO Capital Markets	Outperform	$46	+506.9%
Jun 25, 2026	Initiated	RRaymond James	Strong Buy	$46	+506.9%
May 27, 2026	Initiated	UUBS	Buy	$48	+533.2%
May 21, 2026	Initiated	CCraig Hallum	Buy	$43	+467.3%
May 04, 2026	Initiated	HH.C. Wainwright	Buy	$45	+493.7%
Apr 08, 2026	Initiated	NNeedham	Buy	$37	+388.1%
Apr 07, 2026	Initiated	TTD Cowen	Buy
Mar 19, 2026	Initiated	CCanaccord Genuity	Buy	$35	+361.7%
Nov 21, 2025	Initiated	SStifel	Buy	$28	+269.4%
Nov 21, 2025	Initiated	MMorgan Stanley	Overweight	$34	+348.5%
Nov 21, 2025	Initiated	LLeerink Partners	Outperform	$30	+295.8%
Nov 21, 2025	Initiated	JJefferies	Buy	$32	+322.2%

Oct-06-26 07:00AM	MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics (GlobeNewswire)
Sep-09-26 07:00AM	MapLight Therapeutics to Participate in Upcoming Investor Conference (GlobeNewswire)
Aug-18-26 07:13AM	AstraZenecas win in lung cancer; Sandoz inks a China deal (BioPharma Dive) +5.11%
07:13AM	AstraZeneca scores in lung cancer; Sandoz inks a China deal (BioPharma Dive)
Aug-13-26 04:05PM	MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
09:10AM	Loading…
09:10AM	MapLight Therapeutics Announces $150 Million Private Placement Financing (GlobeNewswire)
Jul-29-26 01:22PM	MapLight CEO on what investors missed in the biotechs schizophrenia data (BioPharma Dive) +22.01%
Jul-28-26 11:06AM	MapLight Therapeutics stock crashes on Phase II schizophrenia data (Clinical Trials Arena) +24.28%
Jul-27-26 07:08PM	MPLT Stock Plunges 73% Wipes Out Over $1B In Market Cap After Trial Miss On Once-Daily Dose (Stocktwits) -72.91%
07:00AM	MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia (GlobeNewswire)
Jul-21-26 09:40AM	Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls (The Fly)
Jun-24-26 07:00AM	MapLight Therapeutics Announces Changes to Board of Directors (GlobeNewswire) +7.02%
Jun-22-26 07:00AM	MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder (GlobeNewswire)
May-14-26 04:05PM	MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
May-08-26 07:00AM	MapLight Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.16%
07:00AM	Loading…
May-01-26 07:00AM	MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results (GlobeNewswire)
Mar-26-26 07:00AM	MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire) +6.01%
Mar-02-26 07:00AM	MapLight Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-09-26 07:00AM	MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026 (GlobeNewswire)
Jan-05-26 07:00AM	MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis (GlobeNewswire)
Dec-16-25 07:00AM	SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies (GlobeNewswire)
Dec-04-25 07:00AM	MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress (GlobeNewswire) +8.39%
Nov-07-25 07:26PM	MapLight Therapeutics, Gold Royalty, and More Stocks See Action From Activist Investors (Barrons.com)
Oct-29-25 09:06AM	MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Oct-26-25 05:30PM	MapLight Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kreitzer Anatol	Chief Discovery Officer	Oct 15 '26	Sale	7.84	12,248	96,024	168,678	Oct 16 05:00 PM
GILLIS JONATHAN	CAO and Interim CFO	Oct 15 '26	Sale	8.08	10,167	82,149	142,315	Oct 16 05:00 PM
Lillie James Woodruff	Chief Scientific Officer	Oct 15 '26	Sale	8.08	11,513	93,025	198,597	Oct 16 05:00 PM
Hanson Kristopher	General Counsel	Oct 15 '26	Sale	8.08	9,020	72,882	128,024	Oct 16 05:00 PM
Foff Erin Pennock	Chief Medical Officer	Oct 15 '26	Sale	8.08	15,355	124,068	296,906	Oct 16 05:00 PM
Kroeger Christopher A.	Chief Executive Officer	Oct 15 '26	Sale	8.08	73,691	595,423	1,195,909	Oct 16 05:00 PM
Hanson Kristopher	Officer	Oct 15 '26	Proposed Sale	7.81	9,020	70,446		Oct 15 06:35 PM
GILLIS JONATHAN	Officer	Oct 15 '26	Proposed Sale	7.81	10,167	79,404		Oct 15 05:44 PM
Foff Erin Pennock	Officer	Oct 15 '26	Proposed Sale	7.81	15,355	119,922		Oct 15 05:30 PM
Kroeger Christopher A.	Officer	Oct 15 '26	Proposed Sale	7.81	73,691	575,527		Oct 15 05:26 PM
Lillie James Woodruff	Officer	Oct 15 '26	Proposed Sale	7.81	11,513	89,917		Oct 15 05:15 PM
ROBERT MALENKA	Director	Oct 15 '26	Proposed Sale	7.81	14,809	115,658		Oct 15 04:37 PM
Anatol Kreitzer	Officer	Oct 15 '26	Proposed Sale	7.81	12,500	97,625		Oct 15 04:09 PM
Hanson Kristopher	General Counsel	Sep 16 '26	Sale	11.67	16,509	192,660	137,044	Sep 18 04:15 PM
Hanson Kristopher	Officer	Sep 16 '26	Proposed Sale	12.08	16,509	199,429		Sep 16 04:20 PM
Catalyst4, Inc.	10% Owner	Aug 14 '26	Buy	11.38	4,400,000	50,072,000	25,306,689	Aug 18 06:55 PM
Lillie James Woodruff	Chief Scientific Officer	Aug 03 '26	Sale	12.54	22,082	276,908	202,380	Aug 04 08:39 PM
Lillie James Woodruff	Officer	Aug 03 '26	Proposed Sale	13.02	22,082	287,508		Aug 03 04:00 PM
Novo Holdings A/S	Former Affiliate	Jul 30 '26	Proposed Sale	15.02	1,600,000	24,032,000		Jul 30 09:08 PM
Catalyst4, Inc.	10% Owner	Jul 30 '26	Buy	13.00	1,000,000	13,000,000	20,906,689	Jul 30 06:39 PM
Catalyst4, Inc.	10% Owner	Jul 28 '26	Buy	11.04	206,225	2,276,904	19,903,689	Jul 30 06:39 PM
Catalyst4, Inc.	10% Owner	Jul 29 '26	Buy	12.63	3,000	37,890	19,906,689	Jul 30 06:39 PM
Cox Troy	Director	Jul 28 '26	Buy	9.52	15,620	148,702	15,620	Jul 28 09:14 PM
GILLIS JONATHAN	CAO and Interim CFO	Jul 17 '26	Sale	37.60	18,469	694,463	144,240	Jul 20 06:00 AM
GILLIS JONATHAN	CAO and Interim CFO	Jul 15 '26	Sale	36.51	10,055	367,093	171,164	Jul 20 06:00 AM
GILLIS JONATHAN	CAO and Interim CFO	Jul 16 '26	Sale	36.80	8,455	311,112	162,709	Jul 20 06:00 AM
Kreitzer Anatol	Chief Discovery Officer	Jul 17 '26	Sale	37.60	17,173	645,719	174,906	Jul 20 06:00 AM
Kreitzer Anatol	Chief Discovery Officer	Jul 15 '26	Sale	36.49	10,055	366,940	201,135	Jul 20 06:00 AM
Kreitzer Anatol	Chief Discovery Officer	Jul 16 '26	Sale	36.80	9,056	333,235	192,079	Jul 20 06:00 AM
Kroeger Christopher A.	Chief Executive Officer	Jul 16 '26	Sale	36.79	69,082	2,541,341	1,263,234	Jul 17 09:46 PM
Kroeger Christopher A.	Chief Executive Officer	Jul 15 '26	Sale	36.69	61,778	2,266,457	1,332,316	Jul 17 09:46 PM
Kroeger Christopher A.	Chief Executive Officer	Jul 17 '26	Sale	37.90	16,779	635,924	1,246,455	Jul 17 09:46 PM
Lillie James Woodruff	Chief Scientific Officer	Jul 16 '26	Sale	36.79	8,547	314,412	226,539	Jul 17 09:45 PM
Lillie James Woodruff	Chief Scientific Officer	Jul 15 '26	Sale	36.70	7,643	280,506	235,086	Jul 17 09:45 PM
Lillie James Woodruff	Chief Scientific Officer	Jul 17 '26	Sale	37.90	2,077	78,718	224,462	Jul 17 09:45 PM
Hanson Kristopher	General Counsel	Jul 16 '26	Sale	36.78	8,118	298,616	146,953	Jul 17 09:44 PM
Hanson Kristopher	General Counsel	Jul 15 '26	Sale	36.70	7,260	266,427	155,071	Jul 17 09:44 PM
Hanson Kristopher	General Counsel	Jul 17 '26	Sale	37.90	1,130	42,827	145,823	Jul 17 09:44 PM
Foff Erin Pennock	Chief Medical Officer	Jul 15 '26	Sale	36.64	28,455	1,042,594	317,604	Jul 17 09:43 PM
Foff Erin Pennock	Chief Medical Officer	Jul 16 '26	Sale	36.77	15,047	553,334	302,557	Jul 17 09:43 PM
Foff Erin Pennock	Chief Medical Officer	Jul 17 '26	Sale	37.90	3,656	138,562	298,901	Jul 17 09:43 PM
ANATOL KREITZER	Officer	Jul 17 '26	Proposed Sale	37.22	17,173	639,179		Jul 17 04:21 PM
JONATHAN GILLIS	Officer	Jul 17 '26	Proposed Sale	37.22	18,469	687,416		Jul 17 04:21 PM
Jonathan Gillis	Officer	Jul 15 '26	Proposed Sale	37.91	36,979	1,401,874		Jul 15 07:59 PM
Anatol Kreitzer	Officer	Jul 15 '26	Proposed Sale	37.91	33,605	1,273,966		Jul 15 07:56 PM
Foff Erin Pennock	Officer	Jul 15 '26	Proposed Sale	37.91	48,158	1,825,670		Jul 15 04:44 PM
ROBERT MALENKA	Director	Jul 15 '26	Proposed Sale	37.91	17,537	664,828		Jul 15 04:23 PM
Kroeger Christopher A.	Officer	Jul 15 '26	Proposed Sale	37.91	152,230	5,771,039		Jul 15 04:17 PM
Hanson Kristopher	Officer	Jul 15 '26	Proposed Sale	37.91	16,508	625,818		Jul 15 04:11 PM
Lillie James Woodruff	Officer	Jul 15 '26	Proposed Sale	37.91	18,835	714,035		Jul 15 04:01 PM
Kroeger Christopher A.	Chief Executive Officer	May 18 '26	Sale	27.19	118,235	3,215,000	1,394,094	May 18 09:27 PM
Hanson Kristopher	General Counsel	May 11 '26	Sale	30.13	13,917	419,263	162,331	May 11 09:30 PM
Kroeger Christopher A.	Chief Executive Officer	May 08 '26	Sale	27.69	34,411	952,835	1,526,309	May 11 09:30 PM
Kroeger Christopher A.	Chief Executive Officer	May 07 '26	Sale	28.65	20,100	575,797	1,560,720	May 11 09:30 PM
Kroeger Christopher A.	Chief Executive Officer	May 11 '26	Sale	30.11	13,980	421,002	1,512,329	May 11 09:30 PM
Foff Erin Pennock	Chief Medical Officer	May 07 '26	Sale	28.54	4,438	126,640	346,059	May 11 09:30 PM
Lillie James Woodruff	Chief Scientific Officer	May 07 '26	Sale	28.28	721	20,390	242,729	May 11 09:30 PM
Setia Vishwas	Chief Financial Officer	May 04 '26	Sale	28.11	14,904	418,930	377,723	May 06 08:15 PM
Setia Vishwas	Chief Financial Officer	May 05 '26	Sale	28.20	10,903	307,444	366,820	May 06 08:15 PM
Setia Vishwas	Chief Financial Officer	May 06 '26	Sale	28.24	10,564	298,345	356,256	May 06 08:15 PM
Foff Erin Pennock	Chief Medical Officer	May 06 '26	Sale	28.76	24,052	691,749	350,497	May 06 08:15 PM
Foff Erin Pennock	Chief Medical Officer	May 04 '26	Sale	27.96	15,652	437,629	385,125	May 06 08:15 PM
Foff Erin Pennock	Chief Medical Officer	May 05 '26	Sale	28.20	10,576	298,216	374,549	May 06 08:15 PM
Lillie James Woodruff	Chief Scientific Officer	May 06 '26	Sale	28.76	24,811	713,599	243,450	May 06 08:15 PM
Lillie James Woodruff	Chief Scientific Officer	May 04 '26	Sale	27.96	15,801	441,813	279,356	May 06 08:15 PM
Lillie James Woodruff	Chief Scientific Officer	May 05 '26	Sale	28.20	11,095	312,839	268,261	May 06 08:15 PM
Hanson Kristopher	General Counsel	May 04 '26	Sale	27.89	13,917	388,177	176,248	May 06 08:15 PM
Kroeger Christopher A.	Chief Executive Officer	May 06 '26	Sale	28.76	23,701	681,583	1,580,820	May 06 08:15 PM
Kroeger Christopher A.	Chief Executive Officer	May 04 '26	Sale	27.96	15,571	435,363	1,614,993	May 06 08:15 PM
Kroeger Christopher A.	Chief Executive Officer	May 05 '26	Sale	28.20	10,472	295,289	1,604,521	May 06 08:15 PM
Kroeger Christopher A.	Officer	May 04 '26	Proposed Sale	30.70	236,470	7,259,629		May 04 05:47 PM
Setia Vishwas	Officer	May 04 '26	Proposed Sale	30.70	36,371	1,116,590		May 04 05:28 PM
Foff Erin Pennock	Officer	May 04 '26	Proposed Sale	30.70	54,718	1,679,843		May 04 05:22 PM
Lillie James Woodruff	Officer	May 04 '26	Proposed Sale	30.70	52,428	1,609,540		May 04 05:20 PM
Hanson Kristopher	Officer	May 04 '26	Proposed Sale	30.70	27,834	854,504		May 04 05:18 PM
GILLIS JONATHAN	CAAO and PAO	Apr 27 '26	Sale	29.74	51,900	1,543,369	199,154	Apr 29 04:30 PM
GILLIS JONATHAN	CAAO and PAO	Apr 28 '26	Sale	30.35	17,935	544,319	181,219	Apr 29 04:30 PM
Kreitzer Anatol	Chief Discovery Officer	Apr 27 '26	Sale	29.66	45,422	1,347,066	211,190	Apr 29 04:30 PM
ANATOL KREITZER	Officer	Apr 27 '26	Proposed Sale	29.76	45,422	1,351,759		Apr 27 04:34 PM
JONATHAN GILLIS	Officer	Apr 27 '26	Proposed Sale	29.76	69,835	2,078,290		Apr 27 04:32 PM
Kreitzer Anatol	Chief Discovery Officer	Apr 15 '26	Sale	26.61	3,316	88,239	256,612	Apr 17 04:05 PM
GILLIS JONATHAN	CAAO and PAO	Apr 15 '26	Sale	26.61	3,590	95,530	251,054	Apr 17 04:05 PM
Hanson Kristopher	General Counsel	Apr 15 '26	Sale	26.80	1,529	40,977	190,463	Apr 17 04:05 PM
Hanson Kristopher	General Counsel	Apr 16 '26	Sale	27.37	298	8,157	190,165	Apr 17 04:05 PM
Setia Vishwas	Chief Financial Officer	Apr 15 '26	Sale	26.87	2,806	75,397	392,743	Apr 17 04:05 PM
Setia Vishwas	Chief Financial Officer	Apr 16 '26	Sale	27.37	116	3,175	392,627	Apr 17 04:05 PM
Lillie James Woodruff	Chief Scientific Officer	Apr 16 '26	Sale	27.37	2,783	76,175	295,157	Apr 17 04:05 PM
Lillie James Woodruff	Chief Scientific Officer	Apr 15 '26	Sale	26.82	1,730	46,399	297,940	Apr 17 04:05 PM
Foff Erin Pennock	Chief Medical Officer	Apr 15 '26	Sale	26.84	2,044	54,861	401,946	Apr 17 04:05 PM
Foff Erin Pennock	Chief Medical Officer	Apr 16 '26	Sale	27.37	1,169	31,998	400,777	Apr 17 04:05 PM
Kroeger Christopher A.	Chief Executive Officer	Apr 16 '26	Sale	27.37	10,052	275,141	1,630,564	Apr 17 04:05 PM
Kroeger Christopher A.	Chief Executive Officer	Apr 15 '26	Sale	26.93	9,135	246,006	1,640,616	Apr 17 04:05 PM
Malenka Robert C.	Director	Apr 15 '26	Sale	26.90	8,593	231,152	316,466	Apr 17 04:05 PM
Anatol Kreitzer	Officer	Apr 15 '26	Proposed Sale	27.02	5,000	135,100		Apr 15 05:20 PM
Jonathan Gillis	Officer	Apr 15 '26	Proposed Sale	27.02	4,000	108,080		Apr 15 05:15 PM
ROBERT MALENKA	Director	Apr 15 '26	Proposed Sale	27.02	8,593	232,183		Apr 15 04:47 PM
Kroeger Christopher A.	Officer	Apr 15 '26	Proposed Sale	27.02	20,822	562,610		Apr 15 04:28 PM
Setia Vishwas	Officer	Apr 15 '26	Proposed Sale	27.02	2,990	80,799		Apr 15 04:17 PM
Lillie James Woodruff	Officer	Apr 15 '26	Proposed Sale	27.02	4,896	132,290		Apr 15 04:14 PM
Hanson Kristopher	Officer	Apr 15 '26	Proposed Sale	27.02	1,827	49,366		Apr 15 04:11 PM

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. It develops the ML-007-MA product for treatment of schizophrenia and ADP. Its platforms include Optogenetics, Transcriptnomics, and STARmap. The company was founded by Christopher A. Kroeger, Karl Deisseroth, Robert Malenka, and Karoly Nikolich in November 2018 and is headquartered in Redwood City, CA.

M.D.Dr. Christopher A. Kroeger M.B.A.

Ph.D.Dr. Robert C. Malenka M.D.

Ph.D.Dr. Erin Pennock Foff M.D.

Founder & Member of Advisory BoardDr. Karoly Nikolich Ph.D.

Ph.D.Dr. Karl Deisseroth M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MapLight Therapeutics Inc

Upgrade your Finviz experience